Cargando…

Protective Effect and Possible Mechanisms of Astragaloside IV in Animal Models of Diabetic Nephropathy: A Preclinical Systematic Review and Meta-Analysis

Astragaloside IV (AS-IV) has a variety of biological activities and is widely used to treat kidney diseases. We conducted a systematic review of 24 animal studies including 424 animals to evaluate the efficacy of AS-IV for diabetic nephropathy (DN); all current possible mechanisms were summarized. A...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Hong, Zhuang, Zhuang, Huang, Yue-Yue, Zhuang, Zhi-Zhi, Jin, Yi, Ye, Han-Yang, Lin, Xiao-Ji, Zheng, Qun, Wang, Yi-Luan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7339662/ https://www.ncbi.nlm.nih.gov/pubmed/32695006 http://dx.doi.org/10.3389/fphar.2020.00988

Ejemplares similares

Astragaloside IV Exerts Cardioprotection in Animal Models of Viral Myocarditis: A Preclinical Systematic Review and Meta-Analysis
por: Zhuang, Zhuang, et al.
Publicado: (2019)

Review on the protective mechanism of astragaloside IV against cardiovascular diseases
por: Yang, Chunkun, et al.
Publicado: (2023)

A Preclinical Systematic Review and Meta-Analysis of Astragaloside IV for Myocardial Ischemia/Reperfusion Injury
por: Zheng, Qun, et al.
Publicado: (2018)

Astragaloside IV improves the pharmacokinetics of febuxostat in rats with hyperuricemic nephropathy by regulating urea metabolism in gut microbiota
por: Zhao, Zhen Xiong, et al.
Publicado: (2022)

Ligustrazine Exerts Cardioprotection in Animal Models of Myocardial Ischemia/Reperfusion Injury: Preclinical Evidence and Possible Mechanisms
por: Zheng, Qun, et al.
Publicado: (2018)

Effect of Astragaloside IV on improving cardiac function in rats with heart failure: a preclinical systematic review and meta-analysis
por: Zhang, Zhiyuan, et al.
Publicado: (2023)

Astragaloside IV, as a potential anticancer agent
por: Xia, Dongqin, et al.
Publicado: (2023)

Astragaloside IV for Experimental Focal Cerebral Ischemia: Preclinical Evidence and Possible Mechanisms
por: Wang, Hui-Lin, et al.
Publicado: (2017)

Astragaloside IV Attenuates the Myocardial Injury Caused by Adriamycin by Inhibiting Autophagy
por: Luo, Li-Fei, et al.
Publicado: (2021)

Elucidation of the binding mechanism of astragaloside IV derivative with human serum albumin and its cardiotoxicity in zebrafish embryos
por: Wu, You-Jiao, et al.
Publicado: (2022)

Astragaloside IV Attenuates Podocyte Apoptosis Mediated by Endoplasmic Reticulum Stress through Upregulating Sarco/Endoplasmic Reticulum Ca(2+)-ATPase 2 Expression in Diabetic Nephropathy
por: Guo, Hengjiang, et al.
Publicado: (2016)

Protective effect of Astragaloside IV on chronic intermittent hypoxia-induced vascular endothelial dysfunction through the calpain-1/SIRT1/AMPK signaling pathway
por: Zhao, Fang, et al.
Publicado: (2022)

Traditional Chinese Medicine for Coronary Heart Disease: Clinical Evidence and Possible Mechanisms
por: Zhang, Ke-Jian, et al.
Publicado: (2019)

Danshensu for Myocardial Ischemic Injury: Preclinical Evidence and Novel Methodology of Quality Assessment Tool
por: Bao, Xiao-yi, et al.
Publicado: (2018)

A Mechanistic Exploratory Study on the Therapeutic Efficacy of Astragaloside IV Against Diabetic Retinopathy Revealed by Network Pharmacology
por: Zhao, Zhi-Hao, et al.
Publicado: (2022)

Identification of Hub Genes in Protective Effect of Astragaloside IV on Aconitine-Induced Cardiac Damage in Zebrafish Based on Bioinformatics Analysis
por: Wang, Mingzhu, et al.
Publicado: (2020)

Suppressing NK Cells by Astragaloside IV Protects Against Acute Ischemic Stroke in Mice Via Inhibiting STAT3
por: Li, Shichun, et al.
Publicado: (2022)

Therapeutic Potential of Astragaloside IV Against Adriamycin-Induced Renal Damage in Rats via Ferroptosis
por: Qin, Lu-Yun, et al.
Publicado: (2022)

Astragaloside IV promotes pharmacological effect of Descurainia sophia seeds on isoproterenol-induced cardiomyopathy in rats by synergistically modulating the myosin motor
por: Liu, Xingkai, et al.
Publicado: (2022)

Protective effects and possible mechanisms of catalpol against diabetic nephropathy in animal models: a systematic review and meta-analysis
por: Fu, Zhongmei, et al.
Publicado: (2023)

Astragaloside IV Inhibits Galactose-Deficient IgA1 Secretion via miR-98-5p in Pediatric IgA Nephropathy
por: Liu, Caiqiong, et al.
Publicado: (2021)

Transcriptomic Analysis Reveals the Protection of Astragaloside IV against Diabetic Nephropathy by Modulating Inflammation
por: Zhang, Yudi, et al.
Publicado: (2020)

Astragaloside IV Attenuated 3,4-Benzopyrene-Induced Abdominal Aortic Aneurysm by Ameliorating Macrophage-Mediated Inflammation
por: Wang, Jiaoni, et al.
Publicado: (2018)

The Mechanism Actions of Astragaloside IV Prevents the Progression of Hypertensive Heart Disease Based on Network Pharmacology and Experimental Pharmacology
por: Jing, Haoran, et al.
Publicado: (2021)

Calcium Sensing Receptor-Related Pathway Contributes to Cardiac Injury and the Mechanism of Astragaloside IV on Cardioprotection
por: Lu, Meili, et al.
Publicado: (2018)

A Single, Acute Astragaloside IV Therapy Protects Cardiomyocyte Through Attenuating Superoxide Anion-Mediated Accumulation of Autophagosomes in Myocardial Ischemia-Reperfusion Injury
por: Huang, Kai-yu, et al.
Publicado: (2021)

Neuroprotective Effect of Astragaloside IV on Cerebral Ischemia/Reperfusion Injury Rats Through Sirt1/Mapt Pathway
por: Shi, Yi-Hua, et al.
Publicado: (2021)

Fasudil, a Rho-Kinase Inhibitor, Exerts Cardioprotective Function in Animal Models of Myocardial Ischemia/Reperfusion Injury: A Meta-Analysis and Review of Preclinical Evidence and Possible Mechanisms
por: Huang, Yue-yue, et al.
Publicado: (2018)

Astragaloside IV Protects Ethanol-Induced Gastric Mucosal Injury by Preventing Mitochondrial Oxidative Stress and the Activation of Mitochondrial Pathway Apoptosis in Rats
por: Qin, Shumin, et al.
Publicado: (2019)

Astragaloside IV ameliorates diabetic nephropathy by modulating the mitochondrial quality control network
por: Liu, Xinhui, et al.
Publicado: (2017)

Astragaloside IV Improves Bleomycin-Induced Pulmonary Fibrosis in Rats by Attenuating Extracellular Matrix Deposition
por: Li, Liu-Cheng, et al.
Publicado: (2017)

The Astragaloside IV Derivative LS-102 Ameliorates Obesity-Related Nephropathy
por: Li, Ziyu, et al.
Publicado: (2022)

Astragaloside IV attenuates ferroptosis after subarachnoid hemorrhage via Nrf2/HO-1 signaling pathway
por: Liu, Zhuanghua, et al.
Publicado: (2022)

Astragaloside IV Relieves Atherosclerosis and Hepatic Steatosis via MAPK/NF-κB Signaling Pathway in LDLR(−/−) Mice
por: Zhang, Yifan, et al.
Publicado: (2022)

Astragaloside IV Derivative (LS-102) Alleviated Myocardial Ischemia Reperfusion Injury by Inhibiting Drp1(Ser616) Phosphorylation-Mediated Mitochondrial Fission
por: Chen, Li, et al.
Publicado: (2020)

Astragaloside IV Alleviates Intestinal Barrier Dysfunction via the AKT-GSK3β-β-Catenin Pathway in Peritoneal Dialysis
por: He, Jiaqi, et al.
Publicado: (2022)

Astragaloside IV promotes the proliferation and migration of osteoblast-like cells through the hedgehog signaling pathway
por: Guo, Li-Hua, et al.
Publicado: (2019)

Notoginsenoside R1 for Organs Ischemia/Reperfusion Injury: A Preclinical Systematic Review
por: Tong, Qiang, et al.
Publicado: (2019)

Astragaloside IV Exerts Cognitive Benefits and Promotes Hippocampal Neurogenesis in Stroke Mice by Downregulating Interleukin-17 Expression via Wnt Pathway
por: Sun, Li, et al.
Publicado: (2020)

Astragaloside IV protects against diabetic nephropathy via activating eNOS in streptozotocin diabetes-induced rats
por: Fan, Yuyan, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_aj0ktp3ftb227ga053lm30t16v